

The National Audit of Primary Breast Cancer (NAOPri) aims to report on patients diagnosed with primary breast cancer in NHS hospitals in England & Wales.

The NAOPri builds on the work of the National Audit of Breast Cancer in Older Patients (NABCOP) and for the first time will include women and men of all ages with primary breast cancer.


The information below is a summarised version of the main scoping work presented within the NAOPri Scoping Document. For further detail on the aspects covered below, please read the full published document available via

<https://www.natcan.org.uk/audits/primary-breast/resources-2/>

Primary breast cancer

- includes breast cancer which, at diagnosis, has not spread beyond the breast or nearby lymph nodes to other parts of the body
- includes non-invasive (stage 0), early invasive (stages 1 to 3A) and locally advanced (3B-C) breast cancer.
- accounts for nearly all (≥95%) of new breast cancers diagnosed

Typical primary breast cancer care pathway








Patient subgroups highlighted:

- Triple negative breast cancer
- Age (young and older)
- Male patients



What are the priority areas for quality improvement?

-  Reduce variation in surgical care.
-  Reduce variation in oncological treatments.
-  Improve short-, medium-, and long-term outcomes.
-  Improve the movement of patients across the care pathway.
-  Improve data completion & quality.

How will the audit share findings with NHS organisations?

- Annual State of the Nation reports.
- Quarterly online dashboards, to support ongoing local quality improvement.

How has the scope of the NAOPri been developed?



- Review of work previously done by the NABCOP
- Review of the wider literature (including external quality standards)
- Consultation with stakeholders on priorities for audit.

How has the NAOPri engaged with stakeholders so far?



- Sharing the new audit at professional organisation meetings.
- Meeting with clinicians & patients at an initial Audit Advisory Committee meeting to discuss priorities and share early indicator thoughts.
- Conducting a scoping survey from February to April 2023.

What did we find from the scoping survey responses?

613 survey respondents for NAOPri questions

including 83 surgeons, 77 oncologists, 70 nurses, and 288 patients/patient advocates.

Survey responses highlighted:

- areas of care considered to be most in need of improvement, and
- important patient subgroups for the audit to focus on.



Which patients will the NAOPri include?

- ✓ All patients (male and female) with a recorded diagnosis of non-invasive or invasive breast cancer (ICD-10 C50; D05) with no evidence of metastatic spread.
- ✓ Aged ≥18 years at diagnosis.
- ✓ Diagnosed in an NHS hospital within England and Wales.

What data will the audit use?

- Existing national cancer datasets linked to other relevant health care datasets to ↓ burden of data collection for staff & patients.
- Data will be provided by:
 - National Disease Registration Service (NDRS) – England
 - Wales Cancer Network (WCN) – Wales

What other things are there to consider?

- Data availability and completeness for key data items.

